Suven Life Sciences quarterly results and financials

Suven Life Sciences (SUVEN)₹279.95+2.06%(9 Nov 2026 close)Healthcare Research, Analytics & Technology

Key facts

In the Jun 2026 quarter (consolidated), Suven Life Sciences reported sales of ₹4.01 Cr, up 99.5% from Jun 2025, and net profit of −₹128 Cr. For the year to Mar 2026, sales were ₹6.99 Cr and net profit −₹276 Cr.

Sales (Jun 2026): ₹4.01 Cr
Net profit (Jun 2026): −₹128 Cr
Sales (FY Mar 2026): ₹6.99 Cr
Net profit (FY Mar 2026): −₹276 Cr
EPS (Jun 2026): ₹−4.84
Borrowings (Mar 2026): ₹16.95 Cr

Company filings, consolidated accounts; latest reported quarter Jun 2026

Suven Life Sciences quarterly results

₹ crore unless stated; each column is a quarter.

Suven Life Sciences Quarterly results
	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	3.01	2.01	2.01	1.01	3.01	2.01	1.01	2.01	1.01	3.01	1.99	4.01
Expenses	26.96	48.92	32.94	31.91	54.91	40.90	44.92	52.89	80.84	106	51.86	136
Operating Profit	−23.97	−45.94	−29.97	−30.98	−51.95	−38.97	−43.98	−50.99	−79.90	−103	−50.99	−132
OPM %	−768.1%	−1,885.1%	−1,267.1%	−3,024.1%	−2,032.0%	−2,435.1%	−2,981.1%	−2,714.1%	−8,671.1%	−3,678.1%	−3,331.1%	−3,711.1%
Other Income	12.97	5.99	3.99	3.99	3.99	1.99	0.99	0.99	3.99	2.99	6.98	7.98
Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation	2.01	2.01	2.01	1.01	1.01	2.01	1.01	1.01	1.01	1.01	2.01	2.01
Profit before tax	−13.01	−42.01	−28.01	−27.99	−49.99	−38.99	−44.06	−52.06	−76.99	−102	−45.99	−128
Tax %	0.0%	0.0%	−4.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Exceptional items	7.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit	−12.97	−41.86	−26.93	−27.93	−49.84	−38.90	−43.90	−51.82	−76.79	−102	−45.92	−128
EPS (Rs)	−0.59	−1.92	−1.23	−1.30	−2.29	−1.80	−2.02	−2.37	−3.41	−4.50	−1.74	−4.84

Suven Life Sciences profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Suven Life Sciences Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	499	543	625	286	13.01	13.01	12.02	14.02	12.01	7.01	6.99	10.02
Expenses	397	413	426	299	128	92.85	134	139	140	172	290	374
Operating Profit	102	129	198	−13.99	−116	−79.99	−122	−126	−128	−166	−284	−366
OPM %	20.0%	24.0%	32.0%	−5.0%	−917.1%	−593.1%	−1,032.1%	−929.1%	−1,094.1%	−2,487.1%	−3,999.1%	−3,648.1%
Other Income	18.94	20.96	22.95	26.91	13.96	7.97	4.99	13.96	28.94	10.98	13.97	21.94
Interest	6.01	6.01	5.01	2.01	1.01	1.01	1.01	0.00	0.00	0.00	0.00	0.00
Depreciation	18.04	21.05	21.06	11.03	4.01	4.01	4.01	7.02	6.02	6.02	6.02	6.04
Profit before tax	98.05	123	196	0.00	−106	−77.01	−122	−118	−106	−161	−276	−353
Tax %	26.1%	29.1%	37.0%	15,038.0%	−11.0%	−7.0%	0.0%	0.0%	−1.0%	0.0%	0.0%	—
Exceptional items	12.01	14.01	11.02	−3.01	0.00	0.00	4.01	8.01	12.01	5.01	10.02	0.00
Net Profit	71.77	86.75	124	−23.93	−93.72	−71.84	−122	−118	−105	−161	−276	−352
EPS (Rs)	3.77	4.58	6.50	−1.26	−4.95	−3.79	−5.61	−5.43	−4.83	−7.39	−10.50	−14.49
Dividend payout %	35.1%	15.1%	15.0%	−80.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—

Suven Life Sciences balance sheet

₹ crore, at each year end.

Suven Life Sciences Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	12.97	12.96	12.96	12.97	12.98	12.96	12.96	14.96	21.93	21.96	21.95	25.93
Reserves	547	582	653	755	226	131	94.89	81.95	353	248	87.92	565
Borrowings	109	82.66	70.77	33.87	2.99	5.97	4.98	2.99	1.99	0.99	0.00	16.95
Other Liabilities	105	73.64	77.63	117	61.70	32.85	15.92	8.95	11.94	13.93	24.88	15.92
Total Liabilities	772	749	815	918	303	182	128	108	388	285	135	623
Fixed Assets	171	304	305	307	21.91	24.90	20.94	37.88	36.89	27.90	59.78	72.79
CWIP	107	6.99	9.98	24.96	0.00	0.00	4.99	3.99	0.00	0.00	0.00	3.99
Investments	0.00	0.00	301	279	223	0.00	0.00	44.99	46.02	76.02	22.01	181
Other Assets	493	438	199	308	57.90	157	103	21.99	304	181	52.96	367
Inventories	81.84	82.90	92.86	139	0.00	0.00	0.00	0.00	0.00	0.99	0.00	0.00
Trade receivables	39.85	53.85	45.88	61.86	2.99	1.99	1.99	0.99	0.99	0.99	0.99	1.99
Cash & equivalents	280	241	9.01	28.03	1.01	15.02	47.01	6.01	184	164	38.03	337
Total Assets	772	749	815	918	303	182	128	108	388	285	135	623

Suven Life Sciences cash flow

₹ crore, for each year.

Suven Life Sciences Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	143	67.77	109	69.73	−52.84	−134	−95.63	−128	−116	−115	−154	−299
Cash from investing activity	−110	−38.93	−311	−0.99	29.93	146	55.94	−21.96	−248	93.83	155	−462
Cash from financing activity	179	−67.86	−29.93	−51.89	4.99	2.99	34.94	146	396	−0.99	−0.99	755
Net cash flow	212	−38.92	−232	16.97	−17.96	13.97	−4.99	−3.99	31.95	−21.94	−0.99	−4.99
Capex	118	57.85	30.92	41.89	39.95	1.99	5.98	19.96	2.99	0.00	36.95	4.99
Free cash flow	24.93	9.96	78.71	27.91	−91.60	−137	−102	−146	−119	−113	−192	−304
CFO / OP %	113.0%	93.0%	111.0%	57.0%	262.0%	114.0%	119.0%	104.0%	91.0%	95.0%	93.0%	106.0%

Suven Life Sciences ratios

Working-capital days and returns, by year.

Suven Life Sciences Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	28	39	31	36	3	66	48	40	22	40	73	78
Inventory days	164	182	221	328	0	—	—	—	—	—	—	—
Days payable	89	78	91	134	—	—	—	—	—	—	—	—
Cash conversion cycle	106	145	163	232	4	67	49	41	23	41	74	79
Working capital days	48	54	41	81	22	703	1,083	233	264	100	−441	505
ROCE %	—	12.9%	14.9%	23.9%	−4.0%	−54.1%	−58.1%	−118.1%	−53.1%	−36.1%	−87.1%	−80.1%

Suven Life Sciences: frequently asked questions

What are the latest quarterly results of Suven Life Sciences?

For the Jun 2026 quarter, Suven Life Sciences reported sales of ₹4.01 Cr, up 99.5% year on year and net profit of −₹128 Cr. The operating margin was −3,711.1%.

What is the annual revenue of Suven Life Sciences?

Suven Life Sciences' sales for the year to Mar 2026 were ₹6.99 Cr; over the last twelve months they were ₹10.02 Cr.

What is the net profit of Suven Life Sciences?

Net profit for the year to Mar 2026 was −₹276 Cr, and −₹352 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−14.49.

How much debt does Suven Life Sciences have?

Suven Life Sciences reported borrowings of ₹16.95 Cr at Mar 2026, against cash and equivalents of ₹337 Cr.

What is the free cash flow of Suven Life Sciences?

Cash from operations was −₹299 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹304 Cr.

Loading…